Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net loss	$ (159,307)	$ (110,936)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,005	810
Research and development license expense	3,500	1,250
Stock-based compensation	5,937	13,940
Change in fair value of warrant liability	100,456
Issuance costs for pre-funded warrant liability	2,567
Impairment of long-lived assets	616
Non-cash lease expense	908	1,031
Other	581	616
Changes in operating assets and liabilities:
Prepaid expenses and other assets	4,008	1,980
Accounts payable	(1,065)	(3,217)
Accrued expenses and other liabilities	(4,260)	(8,576)
Deferred revenue	(11,847)
Net cash used in operating activities	(56,901)	(103,102)
Cash flows from investing activities
Purchase of research and development license	(3,500)	(4,250)
Purchase of property, plant and equipment	(3,852)	(18,310)
Other	10
Net cash used in investing activities	(7,342)	(22,560)
Cash flows from financing activities
Proceeds from issuance of common stock, net of sales commissions		11,640
Proceeds from issuance of common stock and pre-funded warrants from private placement, net of placement agent commissions and other offering costs	140,713
Payment of shelf registration costs	(387)	(319)
Proceeds from common stock issuances under ESPP	68	253
Other	(253)	(709)
Net cash provided by financing activities	140,641	10,865
Net increase (decrease) in cash, cash equivalents and restricted cash	76,398	(114,797)
Cash, cash equivalents and restricted cash at the beginning of the period	90,517	151,740
Cash, cash equivalents and restricted cash at the end of the period	166,915	36,943
Cash and cash equivalents	164,278	34,306
Restricted cash	2,637	2,637
Supplemental disclosure of cash flow information:
Cash paid for interest	3,665	1,758
Supplemental disclosure of noncash investing and financing activities:
Property, plant and equipment in accounts payable and accrued expenses	45	3,366
Right-of-use assets obtained in exchange for lease liabilities		23,035
Offering costs not yet paid	423	$ 40
Issuance of warrants in connection with private placement	252
Private Placement
Cash flows from financing activities
Proceeds from issuance of common stock, net of sales commissions	$ 500